Skip to main content
SpringerLink
Log in

Comment, en Afrique, gérer les comorbidités en hépatologie?

Managing hepatic comorbidities in Africa

  • Published:
Journal Africain d’Hépato-Gastroentérologie

Résumé

La prévalence de l’hépatite B et de l’hépatite C en Afrique est élevée avec d’importantes différences selon les pays, en lien avec des modes de transmission différents. Il existe aussi des différences importantes selon les pays concernant la prévalence de l’excès pondéral et l’obésité mais, globalement leur prévalence est élevée et en augmentation. Ces comorbidités peuvent en elles-mêmes être responsables d’une maladie héptique sévère; mais aussi accroître la sévérité d’une hépatite virale chronique ainsi que diminuer la réponse au traitement antiviral. Ces données épidémiologiques et physiopathologiques expliquent une fréquente association de ces comorbidités. Quand un traitement est envisagé pour une hépatite B ou C, il est important de prendre en compte ces éventuelles comorbidités.

Abstract

The prevalence of hepatitis B and C is high in Africa, with major differences between countries based on varying transmission routes. Some striking differences have been observed in overweight and obese patients, but, in general, prevalence is high and on the rise. In some countries, alcohol consumption is high. These comorbidities alone could lead to severe liver disease, potentiate the severity of viral induced liver disease and decrease the response to antiviral treatment. Epidemiologic and pathophysiological data have demonstrated a frequent association between these comorbidities. When addressing the treatment of hepatitis B and C, it is important to take into account their possible association with alcohol abuse, overweight and obesity.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Références

  1. (2003–2004) Estimation des taux de prévalence des anticorps anti-VHC et des marqueurs du virus de l’Hépatite B chez les assurés sociaux du régime général de France métropolitaine, www.invs.sante.fr/publications/2005/

  2. Alcool, effets sur la santé, expertise collective Inserm (2001) Éditions Inserm, pp 1–34

  3. Angulo P (2002) Non alcoholic fatty liver disease. N Engl J Med 346:1221–1231

    Article  PubMed  CAS  Google Scholar 

  4. Feld JJ, Ocama P, Ronald A (2005) The liver in HIV in Africa. Antiviral therapy 10: 953–965

    PubMed  Google Scholar 

  5. Crockett SD, Keeffe EB (2005) Natural history and treatment of hepatitis B virus and hepatitis C coinfection. Ann Clin Microbiol Antimicrob 4: 13

    Article  PubMed  Google Scholar 

  6. Mendez MA, Monteiro CA, Popkin BM (2005) Overweight exceeds underweight among women in most developing countries. Am J clin Nutr 81: 714–721

    PubMed  CAS  Google Scholar 

  7. Belahsen R, Mziwira M, Fertat F (2003) Anthropometry of women of chilbearing age in Morocco:body composition and prevalence of overweight and obesity. Public Health Nutrition 7: 523–530

    Article  Google Scholar 

  8. Pasquet P, Temgoua S, Melaman-sego F, et al. (2003) Prevalence of overweight and obesity for urban adults in Cameroon. Ann Hum Biol 30: 551–562

    Article  PubMed  CAS  Google Scholar 

  9. Fezeu L, Minkoulou E, Balkau B, et al. (2005) Association between socioeconomic status and adiposity in urban Cameroon. Internat J Epidemiol 35: 105–111

    Article  Google Scholar 

  10. Patton HM, Patel K, Behling C, et al. (2004) The impact of steatosis on disease progression and early and sustained treatment response in chronic hepatitis C patients. J Hepatol 40: 484–490

    Article  PubMed  Google Scholar 

  11. Mihm S, Fayyazi A, Hartmann H, et al. (1997) Analysis of histopathological manifestations of chronic hepatitis C virus infection with respect to virus genotype. Hepatology 25: 735–739

    Article  PubMed  CAS  Google Scholar 

  12. Kumar D, Farell GC, Fung E, et al. (2002) Hepatitis C virus genotype 3 is cytopathic to hepatocytes: reversal of hepatitis steatosis after sustained therapeutic response. Hepatology 36: 1266–1272

    Article  PubMed  Google Scholar 

  13. Castera L, Hezode C, Roudot-Thoraval F, et al. (2003) Worsening of steatosis is an independent factor of fibrosis progression in untreated patients with chronic hepatitis C and paired liver biopsies. Gut 52: 288–292

    Article  PubMed  CAS  Google Scholar 

  14. Hourigan LF, Mac Donald GA, Purpie D, et al. (1999) Fibrosis in chronic hepatitis C correlates significantly with body mass index and steatosis. Hepatology 29: 1215–1219

    Article  PubMed  CAS  Google Scholar 

  15. Adinolfi LE, Gambardella M, Andreana A, et al. (2001) Steatosis accelerates the progression of liver damage of chronic hepatitis C and correlates with specific HCV genotype and visceral obesity. Hepatology 33: 1358–1364

    Article  PubMed  CAS  Google Scholar 

  16. Mehta SH, Brancati FL, Sulkowski MS, et al. (2000) Prevalence of type 2 diabetes mellitus among persons with hepatitis C infection in United States. Ann Intern Med 1333: 592–599

    Google Scholar 

  17. Monto A, Alonzo J, Watson JJ, et al. (2002) Steatosis in chronic hepatitis C: relative contributions of obesity, diabetes mellitus and alcohol. Hepatology 36: 729–736

    Article  PubMed  Google Scholar 

  18. Patton HM, Patel K, Mc Hutchinson JG (2004) Hepatitic steatosis in chronic hepatitis C virus infection: a review of mechanisms, influence or natural history and treatment outcomes. Hepatology Rev 1: 72–80

    Google Scholar 

  19. Romero Gomez M, Castellano-megias VM, Grande L, et al. (2003) Serum leptin correlate with hepatic steatosis in chronic hepatitis C. Am J Gastroenterol 98: 1135–1141

    PubMed  CAS  Google Scholar 

  20. Shintani Y, Fujie H, Miyoshi H, et al. (2004) Hepatitis C virus infection and diabetes: direct involvement of the virus in the development of insulin resistance. Gastroenterology 126: 840–848

    Article  PubMed  CAS  Google Scholar 

  21. Poynard T, Ratziu V, Mc Hutchinson J, et al. (2003) Effect of treatment with peginterferon or interferon alpha 2b and ribavirin on steatosis in patients infected with hepatitis C. Hepatology 38: 75–85

    Article  PubMed  CAS  Google Scholar 

  22. Sanyal AJ, Contos MJ, Sterling RK, et al. (2003) Non alcoholic fatty liver disease in patients with hepatitis C is associated with features of the metabolic syndrome. Am J Gastroenterol 98: 2064–2071

    Article  PubMed  Google Scholar 

  23. Safdar K, Schiff ER (2004) Alcohol and hepatitis C. Sem Liv Dis 24: 305–313

    Article  Google Scholar 

  24. Pessione F, Degos F, Marcellin P, et al. (1998) Effect of alcohol consumption on serum hepatitis C virus RNA and histological lesions in chronic hepatitis C. Hepatology 27: 1717–1722

    Article  PubMed  CAS  Google Scholar 

  25. Loguercio C, Di Pierro M, Di Marino MP, et al. (2000) Alcohol. Alcohol 35: 29–301

    Google Scholar 

  26. Naveau S, Giraud V, Borotto E, et al. (1997) Excess weight risk factor for alcoholic liver disease. Hepatology 25: 108–111

    Article  PubMed  CAS  Google Scholar 

  27. Poynard T, Bedossa P, Opolon P (1997) Natural history of liver fibrosis progression in patients with chronic hepatitis C. Lancet 349: 825–832

    Article  PubMed  CAS  Google Scholar 

  28. Raynard B, Balian A, Fallik D, et al. (2002) Risk factors of fibrosis in alcohol induced liver disease. Hepatology 35: 635–638

    Article  PubMed  Google Scholar 

  29. Ratziu V, Munteanu M, Charlotte F, et al. (2003) Fibrogenic impact of high serum glucose in chronic hepatitis C. J Hepatol 39: 1049–1055

    Article  PubMed  CAS  Google Scholar 

  30. N’Kontchou G (2003) Impact of overweight, diabetes mellitus and tobacco on the incidence of HCC in patients with alcohol and viral C cirrhosis. Hepatology 38(Suppl 1): 279A

    Google Scholar 

  31. Roudot-Thoraval F, Bastie A, Pawlotsky JM, et al. (1997) Epidemiological factors affecting the severity of hepatitis Cvirus related liver disease: a french survey of 6664 patients. The study group for prevalence and the epidemiology of hepatitis C virus. Hepatology 26: 485–490

    Article  PubMed  CAS  Google Scholar 

  32. Corrao G, Arico S (1998) Independent and combined action of hepatitis C virus infection and alcohol consumption on the risk of symptomatic liver cirrhosis. Hepatology 27: 914–919

    Article  PubMed  CAS  Google Scholar 

  33. Vento S, Cainelli F (2002) Does hepatitis C virus cause severe liver disease only in people who drink alcohol. Lancet Infect Dis 2: 303–309

    Article  PubMed  Google Scholar 

  34. Hezode C, Lonjon I, Roudot-Thoraval F, et al. (2003) Impact of moderate alcohol consumption on histological activity and fibrosis in patients with chronic hepatitis C and specific influence on steatosis: a prospective study. Aliment Pharmacol Ther 17: 1031–1037

    Article  PubMed  CAS  Google Scholar 

  35. Monto A, Patel K, Bostrom A, et al. (2004) Risks of a range of alcohol intake on hepatitis C related fibrosis. Hepatology 39: 826–834

    Article  PubMed  Google Scholar 

  36. Dixon JB, Bhathal PS, O’Brien PE (2001) Nonalcoholic fatty liver disease: predictor of non alcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterology 121: 91–1000

    Article  PubMed  CAS  Google Scholar 

  37. Ionanou GN, Weiss NS, Kowdley KV, et al. (2003) Is obesity a risk factor for cirrhosis-related death or hospitalization? A population-based cohort study. Gastroenterology 125: 1053–1059

    Article  Google Scholar 

  38. Davies MJ, Baer DJ, Judd JT, et al. (2002) Effect of moderate alcohol intake on fasting insulin and glucose sensitivity and insulin sensitivity in postmenopausal women: a randomized controlled trial. JAMA 287: 2559–2562

    Article  PubMed  CAS  Google Scholar 

  39. Cohen P, Guillevin L (2004) Cryoglobulinemies mixtes, maladies à complexes immuns et maladies systemiques liées au virus de l’hépatite C in Hépatite C. Pawlotsky JM, Dhumeaux D. Éditions EDK. Paris, pp 309–324

    Google Scholar 

  40. Abecassis S, Cribier B, Chosidow O (2004) Manifestations dermatologiques associées à l’infection par le virus de l’hépatite C in Hépatite C. Pawlotsky JM, Dhumeaux D. Éditions EDK. Paris, pp 325–332

    Google Scholar 

  41. Eschwege E (2003) The dysmetabolic syndrome, insulin resistance and increased cardiovascular(CV) morbidity and mortality in type 2 diabetes: aetiological factors in the development of CV complications. Diabetes Metab 29: 19–27

    Article  Google Scholar 

  42. Guide pratique pour faire le point sur votre consommation d’alcool. Intervention auprès des consommateurs excessifs d’alcool. www.inpes.santé.fr

  43. Michaud P, Gache P, Batel P, et al. (2003) Intervention brève auprès des buveurs excessifs. Revue du Prat MG 17: 281–289

    Google Scholar 

  44. Hillaire S, Michaud P (2003) Pourquoi faut-il s’intéresser à la consommation d’alcool des malades atteints d’hépatite C? Hepato-Gastro 10: 14–19

    Google Scholar 

  45. Castera L, Constant A, Foucher J, et al. (2003) Étude des représentations culturelles et des « idées reçues » concernant l’hépatite C chez des patients suivis dans un pôle de référence. Gastroenterol Clin Biol 27(abstract)

  46. Aide à l’arrêt du tabac. Les stratégies thérapeutiques médicamenteuses et non médicamenteuses de l’aide à l’arrêt du tabac. Site web: afssaps.sante.fr

  47. Pessione F, Ramond MJ, Njapoum C, et al. (2001) Cigarette smoking and hepatic lesions in patients with chronic hepatitis C. Hepatology 34: 121–125

    Article  PubMed  CAS  Google Scholar 

  48. Hézode C, Lonjon I, Roudot-Thoraval F, et al. (2003) Impact of smoking on histological liver lesions in chronic hepatitis C. Gut 52: 126–129

    Article  PubMed  Google Scholar 

  49. Hickman IJ, Clouston AD, MacDonald GA, et al. (2004) Effect of weight reduction on liver histology and biochemistry in patients with chronic hepatitis C. Gut 53: 413–419

    Article  PubMed  CAS  Google Scholar 

  50. Bringer J, Raingeard I, Renard E (2003) Déceler et traiter l’insulinorésistance et ses conséquences. Post’U FMC HGE(Suppl): 198–202, site web: www.fmcgastro.org

  51. Tuomilehto J, Lindström J, Eriksson JG, et al. (2001) Prevention of type2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 344: 1343–1350

    Article  PubMed  CAS  Google Scholar 

  52. Linström J, Ilanne-Parikka P, Peltonen ME, et al. (2006) Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow-up of the finnish diabetes prevention study the lancet 368: 1673–1679

    Google Scholar 

  53. Wing RR, Tate DF, Gorin AA, et al. (2006) A self-regulation program for maintenance of weight loss. N Engl J Med 355: 1563–1571

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Université Victor-Segalen Bordeaux-II, Hôpital Haut-lévêque, F-33600, Pessac, France

    P. Couzigou

Authors
  1. P. Couzigou
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to P. Couzigou.

About this article

Cite this article

Couzigou, P. Comment, en Afrique, gérer les comorbidités en hépatologie?. J Afr Hepato Gastroenterol 1, 63–70 (2007). https://doi.org/10.1007/s12157-007-0014-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12157-007-0014-9

Mots clés

Keywords

Search

Navigation